Sunway University Shaping the Future of Healthcare Education
The launch of the Sir Jeffrey Cheah Sunway Medical School follows the establishment of the Jeffrey Cheah Biomedical Centre (JCBC) in Cambridge, reinforcing Tan Sri Sir Jeffrey Cheah's commitment to advancing world-class education and biomedical research. The launch ceremony on 7 May 2025 at Sunway University was officiated by Minister of Higher Education, YB Dato' Seri Diraja Dr. Zambry Abd Kadir, and attended by Tan Sri Sir Jeffrey Cheah, Founder and Chairman of Sunway Group. The event also welcomed the presence of international ambassadors, underscoring the global significance of this initiative.
A highlight of the launch was the White Coat Ceremony for the inaugural cohort of medical students, who also took the Hippocratic Oath, a symbolic and meaningful rite of passage marking their official induction into the medical profession.
The Doctor of Medicine (MD) programme at Sunway University offers a dynamic, future-ready medical curriculum anchored by immersive clinical training at Sunway Medical Centre, a leading private quaternary hospital. Here, students gain hands-on experience in patient care, translating medical knowledge into real-world practical skills. The programme also fosters inter professional collaboration, preparing students to work effectively within diverse healthcare teams for a holistic understanding of patient care.
With a strong emphasis on clinical and translational research, sustainability and planetary health in medicine, digital healthcare technology including precision medicine and application of artificial intelligence in medicine, students are equipped to lead in tech-enabled healthcare environments. Beyond the hospital, the programme encourages community engagement through initiatives like the Desa Mentari Project, nurturing socially responsible medical professionals dedicated to service and impact.
Professor Sibrandes Poppema, President of Sunway University, expressed his enthusiasm for this landmark development: "The launch of the Sir Jeffrey Cheah Sunway Medical School represents a pivotal step forward in our mission to shape future-ready healthcare professionals. Our goal is to develop doctors and researchers who not only excel in medical knowledge and clinical skills but who are also equipped to lead with integrity, empathy, and innovation. This school will be a catalyst for transformative research, global collaboration, and sustainable healthcare solutions that benefit communities in Malaysia and beyond."
With its future-ready medical curriculum, state-of-the-art clinical training, digital fluency, and global research collaborations, the Sir Jeffrey Cheah Sunway Medical School is set to become a leading institution in medical education across Asia. Its launch marks a new era of medical education innovation—one that supports the development of sustainable, technology-enhanced, and community-driven healthcare solutions for the future.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
an hour ago
- Korea Herald
[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria
BOSTON and SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- More than 1,200 reported cases of CRE (Carbapenem-Resistant Enterobacteriaceae) infections have been reported in the In-cheon region of South Korea alone between January and April of this year. In addition, in June of this year, a report was released that an investigation had begun into Salmonella infections linked to eggs across seven U.S. states. These and other ongoing reports are raising awareness about the dangers of CRE, a representative Gram-negative bacterium, as infections caused by Gram-negative bacteria are becoming an increasingly serious global issue. Amid the growing trend of infectious disease outbreaks caused by Gram-negative bacteria, we have determined that it is time to move forward with the commercialization of related technologies. Accordingly, we have recently completed U.S. patent applications for three novel endolysin-derived drug candidates showing strong antibacterial activity against Gram-negative and superbugs. These newly patented drug candidates — PKL200, TSL2200, and EAL2200 — were derived from the GN200 development program that has been carried out over the past several years using the proprietary platform technology we named "itLysin." The drug candidate PKL200 demonstrates strong bacteriolytic activity against several major Gram-negative bacteria, including Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Klebsiella aerogenes, and Enterobacter cloacae, including CRE. It also exhibits antibacterial activity against Uropathogenic Escherichia coli (UPEC), which is one of the major causes of urinary tract infections (UTI). PKL200 is considered a highly promising drug candidate with potential for treating various indications, including intestinal CRE clearance, pneumonia, and urinary tract infections. Another drug candidate, TSL2200, is a pipeline that offers rapid bactericidal effects against all types of Salmonella. It is expected to be used to prevent and treat Salmonella infections caused by contaminated eggs, meat, salads, tomatoes, and other foods. Its potential applications extend to the dairy, meat processing, and broader food processing industries, as well as being a treatment for food poisoning. EAL2200 is a pipeline that provides antibacterial activity against bacteria of the Erwinia genus, which cause bacterial diseases in fruit crops, including fire blight. In a situation where there are currently no safe and effective treatments for fire blight, this pipeline is expected to be used as a bio-control agent and therapeutic with biological safety for both the environment and human health. All of the newly patented drug candidates were developed through the itLysin platform, an advanced endolysin technology derived from our long-standing expertise in bacteriophage and endolysin technologies. Traditional antibiotics and other drugs have shown limited effectiveness against Gram-negative bacteria due to the outer membrane barrier. However, the drug candidates developed through the itLysin platform have been designed to more efficiently penetrate the outer membrane structure of Gram-negative bacteria, thereby overcoming the limitations of existing drugs and technologies. This patent application was not merely for the purpose of securing rights but was a strategic decision focused on commercialization. While it was common in the past to file patents first and then seek commercialization opportunities, this time, the patents were filed based on thorough commercialization preparations. This is a strategy that effectively secures rights to the drug candidates and is advantageous in terms of technology security. We are leading the development of new drugs against super bacteria based on our proprietary bacteriophage and endolysin technologies, and we have secured multiple promising pipelines. Recently, we have presented our commercialization strategy through press briefings and corporate presentations. With global pharmaceutical companies showing significant interest due to the lack of effective antibiotics against Gram-negative bacteria worldwide, we plan to accelerate the development of pipelines targeting Gram-negative bacteria based on these recent patent applications. We will continue our efforts to achieve tangible results through various commercialization strategies. it is iNtRON.
Korea Herald
2 days ago
- Korea Herald
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics
SEOUL, South Korea, July 1, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, announced today the launch of STAgora™, a next-generation platform for infectious disease analytics. Designed as a real-time infectious disease intelligence system, the platform combines diagnostic data with advanced statistical modeling and aims to redefine how the world detects, tracks, and responds to outbreaks. STAgora™ provides real-time global visualization of infectious disease trends at the municipal, national, and continental levels, based on actual diagnostic test results. The platform delivers healthcare professionals immediate, structured diagnostic reports and statistical analyses in clear, actionable formats. These are supported by customizable dashboards and real-time alert functions. In addition to tracking individual cases, STAgora™ enables users to monitor outbreaks across selected regions, both local and international. This capability provides real-time visibility into disease spread, enhancing situational awareness and supporting timely, data-driven public health responses. By equipping national and global health authorities with real-time epidemiological insight, the platform is expected to strengthen decision-making and support the development of effective response strategies to mitigate large-scale infectious disease outbreaks. With more than 40 built-in statistical tools, STAgora™ enables early detection of abnormal pathogen patterns and supports predictive modeling for seasonal trends and emerging outbreaks. These tools include modules for tracking individual infections, analyzing symptom-based co-infections and calculating real-time infection rate trends. Together, they help transform static data into forward-looking intelligence that guides proactive interventions. Unlike traditional outbreak monitoring systems that rely on retrospective data, STAgora™ performs real-time analysis of PCR-derived diagnostics. This allows for immediate visibility into pathogen spread and, through AI-based algorithms, the forecasting of potential future outbreaks. "The key differentiator of STAgora™ is its unique architecture, which aggregates real-time diagnostic data from around the world into a unified analysis platform," said Young-Seag Baeg, head of strategic planning at Seegene. When paired with Seegene's proprietary syndromic quantitative PCR technology, STAgora™ offers expanded visibility into both single-pathogen infections and simultaneous multi-pathogen co-infections. This comprehensive diagnostic insight empowers clinicians to make faster, more informed decisions at the point of care. "During the COVID-19 pandemic, we saw firsthand how crucial accurate and timely interpretation of diagnostic data was in shaping public health policies and clinical outcomes," said Daniel Shin, executive vice president and chief global sales and marketing officer at Seegene. "Now, as we confront increasingly complex threats such as antimicrobial resistance, viral mutations and co-infections, the ability to deliver actionable insights from diagnostic data is becoming a cornerstone of clinical innovation and a vital pillar of global health security." Seegene will officially debut STAgora™ at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting, taking place July 27 to 31 in Chicago, USA. The event will highlight key capabilities of the platform, including its integration with CURECA™, Seegene's fully automated, unmanned PCR system. ADLM 2025 will also serve as a launchpad for Seegene to explore global collaboration and partnerships with healthcare leaders and clients. With the launch of STAgora™, Seegene aims to lay the foundation for a smarter, faster and more connected global health defense system. By combining real-time molecular diagnostics, AI-driven analytics and global data integration, STAgora™ represents a strategic step toward building an intelligent public health infrastructure capable of responding proactively to emerging threats. The company envisions the platform as a core pillar of the global infectious disease response framework, marking a new step toward enhanced diagnostic insight and preparedness. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. CURECA™(Continuous, Unlimited, Random-access, Expandable, and Customizable Automation) is a fully automated and modular PCR system that eliminates manual processes and enables continuous, real-time testing. It is a unified platform designed to operate continuously, 24 hours a day, with no human intervention. The very core feature is CPS which is the first part of CURECA™, the world's first automated pre-treatment system capable of handling a full spectrum of specimen types, including blood, stool, sputum, and urine. Designed to support both centralized and decentralized labs, CURECA offers scalable automation and flexible adoption—making it especially valuable in settings with limited space or personnel.
Korea Herald
3 days ago
- Korea Herald
Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs
YONGIN, South Korea, June 30, 2025 /PRNewswire/ -- Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced the release of its 2024–2025 Sustainability Report. Noul has annually assessed its performance in economic, social, and environmental areas and transparently disclosed the results to stakeholders through sustainability reports. This is the company's fifth publication. CEO David Lim stated, "The year 2024 marked the end of Noul's first decade focused on technology development, and the beginning of a new phase of scale-up aimed at delivering business performance and enhancing corporate value. Based on the sustainability capabilities and outcomes built over the years, we strengthened our organizational fundamentals to become a global healthcare company with both profitability and growth." He added, "In the coming decade, we will focus on strengthening product competitiveness and profitability, while continuing R&D investments in cancer diagnostics to secure strong growth momentum." The 2024–2025 Sustainability Report outlines Noul's business activities and outcomes aimed at full-scale scale-up, research and development efforts including product performance validation, and company-wide initiatives to enhance internal execution capabilities. The report also summarizes the economic and social value generated through these activities and includes responses to key stakeholder questions, presenting both current progress and future plans for sustainable growth. Major highlights include: The company also focused company-wide capabilities on building a strong business foundation to convert rising customer interest into actual sales. In the "Stakeholder Q&A" section, Noul provides detailed responses to key topics, such as: The report also transparently discloses improvement efforts and outcomes across Noul's five Sustainability Focus Areas: For each focus area, Noul has presented mid-to-long-term improvement plans along with implementation results and future directions, enhancing stakeholder trust and information accessibility. In addition, third-party assurance was conducted for greenhouse gas emission data to ensure reliability of environmental disclosures. Justin Ahn, Chief Sustainability Officer (CSO), commented: "As a KOSDAQ-listed company, Noul has proactively analyzed stakeholder expectations and established improvement plans. Since 2024, we've enacted a company-wide Code of Conduct encompassing all areas of sustainability. Going forward, we will prioritize stakeholder needs in setting improvement priorities, while enhancing our internal execution capabilities and elevating responsible management practices aligned with global standards." This year's report has been prepared in accordance with the Global Reporting Initiative (GRI) Standards, the most widely recognized international framework for sustainability reporting. A separate GRI Index is included to enhance transparency and usability. Noul reports ESG performance and plans annually to its Board of Directors, while maintaining responsible communication with a wide range of stakeholders, including customers and partners, investors and shareholders, employees, international organizations, and governments. The full report is available at Noul website( and the Korean Financial Supervisory Service's disclosure system ( About Noul Co., Ltd. "Enabling blood and cancer diagnostics anywhere in the world with AI." Founded in December 2015, Noul ( is an on-device AI healthcare company with a mission to explore global challenges that threaten human health and life, discover novel solutions, and realize those possibilities. Noul has commercialized the world's first AI-powered diagnostic lab, miLab™, through convergence of AI, biotechnology, and compact robotics. The miLab™ Platform is the only solution that fully automates the microscopic diagnostic process—from sample preparation to AI-based image analysis—delivering lab-grade blood and cancer diagnostics at the point of care. Within 15 minutes, miLab™ produces precise results even in low-resource settings. In 2022, miLab™ was described in a UNITAID report as "The most advanced digital microscope and fully integrated bench-top platform" for malaria diagnostics. It is now deployed in 28 countries, used by pharmaceutical companies, hospitals, labs, and public health institutions worldwide. With strong clinical validation and proven performance, Noul is rapidly expanding its market presence, especially in malaria, blood analysis, and cervical cancer diagnostics. The company's vision is to make a meaningful impact on the lives of 1 billion people worldwide through accessible, innovative diagnostic technologies.
